4.6 Article

Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin

期刊

HISTOPATHOLOGY
卷 55, 期 3, 页码 277-283

出版社

WILEY-BLACKWELL PUBLISHING, INC
DOI: 10.1111/j.1365-2559.2009.03376.x

关键词

pancreatic cancer; prognosis; resection margin

资金

  1. Cancer Research UK
  2. Medical Research Council [G9900432] Funding Source: researchfish
  3. MRC [G9900432] Funding Source: UKRI

向作者/读者索取更多资源

Aims: The current Royal College of Pathologists guidelines for pancreatoduodenectomy specimen reporting recommend that microscopic evidence of tumour within 1 mm of a resection margin (RM) should be classified as R1. No clinical evidence exists to justify this classification. The aim of this study was to identify the proportion of pancreatoduodenectomy specimens in which 'equivocal' RMs are present (tumour involvement within 1 mm of, but not directly reaching, one or more resection margins) and whether the survival of these patients was similar to that of patients with 'unequivocal' RM involvement. Methods and results: Patients with histologically confirmed pancreatic ductal adenocarcinoma undergoing pancreatoduodenectomy between 1997 and 2007 (n = 163) were identified from a prospective database. One hundred and twenty-eight cases (79%) were classified as R1. Of these, 57 (45% of all R1 cases) were based on 'equivocal' margin involvement. There was no significant difference in overall survival between equivocal and unequivocal R1 resections (log rank, P = 0.102). All R1 resections had a poorer survival on univariate (log rank, P = 0.013), but not multivariate, analysis (Cox, P = 0.132). Conclusions: Our results indicate that cases with microscopic tumour involvement within 1 mm of a resection margin should be considered synonymous with incomplete excision for resected pancreatic cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Gastroenterology & Hepatology

Minimally invasive and endoscopic versus open necrosectomy for necrotising pancreatitis: a pooled analysis of individual data for 1980 patients

Sandra van Brunschot, Robbert A. Hollemans, Olaf J. Bakker, Marc G. Besselink, Todd H. Baron, Hans G. Beger, Marja A. Boermeester, Thomas L. Bollen, Marco J. Bruno, Ross Carter, Jeremy J. French, Djalma Coelho, Bjoern Dahl, Marcel G. Dijkgraaf, Nilesh Doctor, Peter J. Fagenholz, Gyula Farkas, Carlos Fernandez del Castillo, Paul Fockens, Martin L. Freeman, Timothy B. Gardner, Harry van Goor, Hein G. Gooszen, Gerjon Hannink, Rajiv Lochan, Colin J. McKay, John P. Neoptolemos, Atilla Olah, Rowan W. Parks, Miroslav P. Peev, Michael Raraty, Bettina Rau, Thomas Rosch, Maroeska Rovers, Hans Seifert, Ajith K. Siriwardena, Karen D. Horvath, Hjalmar C. van Santvoort

Article Oncology

Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer

Andrea S. Bauer, Petr V. Nazarov, Nathalia A. Giese, Stefania Beghelli, Anette Heller, William Greenhalf, Eithne Costello, Arnaud Muller, Melanie Bier, Oliver Strobel, Thilo Hackert, Laurent Vallar, Aldo Scarpa, Markus W. Buechler, John P. Neoptolemos, Stephanie Kreis, Joerg D. Hoheisel

INTERNATIONAL JOURNAL OF CANCER (2018)

Review Oncology

Optimizing the outcomes of pancreatic cancer surgery

Oliver Strobel, John Neoptolemos, Dirk Jaeger, Markus W. Buechler

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

Article Surgery

The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma

Paula Ghaneh, Jorg Kleeff, Christopher M. Halloran, Michael Raraty, Richard Jackson, James Melling, Owain Jones, Daniel H. Palmer, Trevor F. Cox, Chloe J. Smith, Derek A. O'Reilly, Jakob R. Izbicki, Andrew G. Scarfe, Juan W. Valle, Alexander C. McDonald, Ross Carter, Niall C. Tebbutt, David Goldstein, Robert Padbury, Jennifer Shannon, Christos Dervenis, Bengt Glimelius, Mark Deakin, Alan Anthoney, Markus M. Lerch, Julia Mayerle, Attila Olah, Charlotte L. Rawcliffe, Fiona Campbell, Oliver Strobel, Markus W. Buechler, John P. Neoptolemos

ANNALS OF SURGERY (2019)

Article Surgery

The Liverpool duodenum-and spleen-preserving near-total pancreatectomy can provide long-term pain relief in patients with end-stage chronic pancreatitis

A. R. G. Sheel, R. D. Baron, L. D. Dickerson, P. Ghaneh, F. Campbell, M. G. T. Raraty, V Yip, C. M. Halloran, J. P. Neoptolemos

LANGENBECKS ARCHIVES OF SURGERY (2019)

Article Gastroenterology & Hepatology

Pancreatic cancer incidence and survival and the role of specialist centres in resection rates in England, 2000 to 2014: A population-based study

Aimilia Exarchakou, Georgia Papacleovoulou, Brian Rous, Winnie Magadi, Bernard Rachet, John P. Neoptolemos, Michel P. Coleman

PANCREATOLOGY (2020)

Review Surgery

Severe acute pancreatitis: surgical indications and treatment

Max Heckler, Thilo Hackert, Kai Hu, Cristopher M. Halloran, Markus W. Buechler, John P. Neoptolemos

Summary: Acute pancreatitis is a sudden inflammatory attack of the pancreas, with a mortality rate of 15-20% in severe cases. Early and accurate diagnosis is crucial for initiating appropriate treatment and improving survival rates. Intensive monitoring and management is necessary for severe cases, with a focus on preventing multi-organ failure and implementing effective treatments for local complications.

LANGENBECKS ARCHIVES OF SURGERY (2021)

Article Cell Biology

Impaired autophagy increases susceptibility to endotoxin-induced chronic pancreatitis

L. Xia, Z. Xu, X. Zhou, F. Bergmann, N. Grabe, M. W. Buechler, J. P. Neoptolemos, T. Hackert, G. Kroemer, F. Fortunato

CELL DEATH & DISEASE (2020)

Article Surgery

The in situ near-total pancreatectomy (LIVOCADO procedure) for end-staged chronic pancreatitis

Ryan D. Baron, Andrea R. G. Sheel, Ammad Farooq, Joerg Kleeff, Pietro Contin, Christopher M. Halloran, John P. Neoptolemos

Summary: The Livocado procedure is a safe and successful option for patients with chronic pancreatitis complicated by vascular involvement. Post-operative pain scores significantly improved, with two-thirds of patients being completely pain-free at 12 months, and employment rehabilitation rates also increased significantly.

LANGENBECKS ARCHIVES OF SURGERY (2021)

Review Gastroenterology & Hepatology

UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better

Patrick Michl, Matthias Lohr, John P. Neoptolemos, Gabriele Capurso, Vinciane Rebours, Nuria Malats, Mathilde Ollivier, Luigi Ricciardiello

Summary: Pancreatic ductal adenocarcinoma is a deadly cancer with scarce research funding in Europe, calling for public-private partnerships to support research and improve treatment methods.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2021)

Editorial Material Oncology

The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain

Christoph Springfeld, John P. Neoptolemos

Summary: Pancreatic ductal adenocarcinoma (PDAC) patients typically have poor prognosis, and even after curative resection, most patients experience disease relapse and ultimately die. However, adjuvant chemotherapy has significantly improved outcomes for patients eligible for surgery. The PREOPANC trial provides evidence supporting neoadjuvant therapy for patients with borderline resectable PDACs, but not for those with resectable tumors.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Letter Oncology

The NEONAX study

M. W. Buechler, J. P. Neoptolemos

ANNALS OF ONCOLOGY (2023)

Review Oncology

Neoadjuvant therapy for pancreatic cancer

Christoph Springfeld, Cristina R. Ferrone, Matthew H. G. Katz, Philip A. Philip, Theodore S. Hong, Thilo Hackert, Markus W. Buechler, John Neoptolemos

Summary: This article discusses the treatment strategies for pancreatic ductal adenocarcinoma (PDAC), including surgical resection and systemic chemotherapy. Neoadjuvant chemotherapy may improve the survival outcomes of patients with borderline-resectable PDAC. For patients with unresectable PDAC, undergoing chemotherapy may lead to surgical resection and improved survival outcomes.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

Letter Oncology

Interpreting Primary End Points in Randomized Trials of Pancreatic Cancer

Christoph Springfeld, Markus W. Buchler, John P. Neoptolemos

JOURNAL OF CLINICAL ONCOLOGY (2023)

Review Cell Biology

Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival

Peter Bailey, Xu Zhou, Jingyu An, Teresa Peccerella, Kai Hu, Christoph Springfeld, Markus Buechler, John P. Neoptolemos

Summary: Pancreatic cancer is a highly lethal cancer, especially in Europe and North America. Combination therapies have improved survival in the short and medium term. Early diagnosis and aggressive treatment have the best chance for long-term survival. Metastatic pancreatic cancer is difficult to treat and often only palliative options are available.

FUNCTION (2023)

暂无数据